Mylan Institutional, Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Mylan Institutional, Inc Pharmaceutical Import Records from India — 8 Products, $11.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylan Institutional, Inc — Pharmaceutical Importer Profile (2026) | 8 Products, $11.5M Trade | TransData Nexus

Mylan Institutional, Inc

Pharmaceutical Importer · United States · Antibiotics Focus · $11.5M Total Trade · DGFT Verified

Mylan Institutional, Inc is a pharmaceutical importer based in United States with a total trade value of $11.5M across 8 products in 4 therapeutic categories. Based on 250 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Mylan Institutional, Inc sources from 3 verified Indian suppliers, with Mylan Laboratories Limited accounting for 89.6% of imports.

Mylan Institutional, Inc — Import Portfolio & Supplier Network

Mylan Institutional, Inc import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mylan Institutional, Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$1.2M	26	89.6%
Steriscience Specialties Private Limited	$91.0K	2	6.7%
Gland Pharma Limited

What Formulations Does Mylan Institutional, Inc Import?

Formulation	Value	Ships
Vancomycin hydrochloride for injection	$500.0K	10
Vancomycin hcl foi USP-1g-10s-mylan-us	$300.0K	6
Sodium phenylacetate and sodium	$50.0K	1
Leucovorin calcium foi 350MG-1s-mylan-usbatch no.7608920 (taxable value inr 9418785.36)	$50.0K	1
Dexmedeto hcl-4mcg-100ML-10s-mylan us batch no:7609458 taxable value:16839562.75(cas no:113775-47-6)	$50.0K	1
Norepinephr bitar INJ 1MG 4ML 10s myl usbatch no	$50.0K	1
Dexametha sod ij USP 4MG ML 1ML 25 myanbatch no	$50.0K	1
Vancomycin hcl foi USP 1g 10s mylan us batch no a2630041 cas no	$50.0K	1
Vancomycin hcl foi USP 1g 10s mylan us batch no a2630042 cas no	$50.0K	1
Pamidronate disodium injection (3MG/ML)(10ML)(1s) (mylan,us) ndc : 67457-446-10and anda no - 078520 batch no	$50.0K	1
Vanco hcl foi USP 750MG 10s mylan us batch no	$44.2K	1
Vanco hcl foi USP 750MG 10s mylan us batch no	$43.2K	1
Naloxone hydrochloride injection usp1mg/ml2ml1susbatch no:5100349	$41.0K	1
Acetaminophe INJ 1000MG/100ML-24s-myl usbatch no:7609455 taxable value:2439384.46(cas no: 103-90-2)	$29.2K	1
Batch no a3130001 (a3130002) a3130001	$0	1

Mylan Institutional, Inc imports 15 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Vancomycin	Antibiotics	$5.3M	106	4.8%	2
2	Famotidine	Gastrointestinal	$2.6M	72	4.6%	3
3	Ampicillin	Antibiotics	$1.2M	24	0.8%	13
4	Doxycycline	Antibiotics	$900.0K	18	0.8%	7
5	Gemcitabine	Oncology	$550.0K	11	1.2%	7
6	Oxaliplatin	Advanced Oncology	$400.0K	8	0.5%	13
7	Tobramycin	Antibiotics	$350.0K	7	0.9%	19
8	Doxorubicin	Oncology	$200.0K	4	0.3%	17

Mylan Institutional, Inc imports 8 pharmaceutical products across 4 categories into United States totaling $11.5M.

Mylan Institutional, Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mylan Institutional, Inc. is a U.S.-based pharmaceutical importer specializing in the procurement of finished pharmaceutical formulations from international suppliers, particularly India. The company operates as a subsidiary of Viatris Inc., a global healthcare company formed in November 2020 through the merger of Mylan and Upjohn, Pfizer's off-patent medicine division. Headquartered in Rockford, Illinois, Mylan Institutional plays a pivotal role in the United States pharmaceutical distribution network by sourcing and importing a diverse range of pharmaceutical products to meet domestic demand.

As a key player in the pharmaceutical supply chain, Mylan Institutional collaborates with various stakeholders, including group purchasing organizations, wholesalers, hospitals, and specialty pharmacies, to ensure the availability of essential medications across the United States. The company's strategic focus on importing finished pharmaceutical formulations enables it to provide a comprehensive portfolio of products, encompassing therapeutic areas such as antibiotics, gastrointestinal treatments, and oncology therapies. This approach aligns with the broader objectives of Viatris Inc., which aims to provide access to medicines and sustainable healthcare solutions worldwide.

2Distribution Network

Mylan Institutional's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across the United States. The company operates a centralized warehouse located at 12720 Dairy Ashford Rd, Sugar Land, Texas, serving as a key hub for logistics and distribution activities. This facility is equipped with advanced logistics capabilities, including temperature-controlled storage and automated inventory management systems, to maintain the integrity and quality of pharmaceutical products.

Geographically, Mylan Institutional's distribution network extends nationwide, ensuring timely and reliable delivery to various healthcare providers, including hospitals, clinics, and pharmacies. The company's logistics operations are supported by a fleet of refrigerated trucks and partnerships with third-party logistics providers, enabling efficient transportation of products from the warehouse to end-users. Additionally, Mylan Institutional leverages digital platforms and data analytics to optimize supply chain operations, monitor inventory levels, and forecast demand, thereby enhancing the responsiveness and resilience of its distribution network.

3Industry Role

Within the United States pharmaceutical supply chain, Mylan Institutional, Inc. functions primarily as a pharmaceutical importer and distributor. The company focuses on sourcing finished pharmaceutical formulations from international suppliers, particularly from India, and importing them into the U.S. market. By doing so, Mylan Institutional ensures the availability of a diverse range of medications, including generic and specialty drugs, to meet the needs of various healthcare providers and patients.

Mylan Institutional's role is distinct from that of primary wholesalers, parallel importers, hospital suppliers, or logistics intermediaries. While it collaborates with wholesalers and hospital suppliers to distribute products, its core function centers on the importation and distribution of finished pharmaceutical products sourced from international markets. This specialization allows Mylan Institutional to focus on quality assurance, regulatory compliance, and supply chain management, ensuring that imported products meet the stringent standards required for the U.S. market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mylan Institutional, Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Mylan Institutional's sourcing strategy exhibits a high degree of concentration, with a significant portion of its imported pharmaceutical products originating from a limited number of suppliers. Notably, the company has imported approximately $1.2 million worth of products from Mylan Laboratories Limited, accounting for 89.6% of its total shipments from India. This concentration indicates a strong reliance on a single supplier for the majority of its imported products.

The shipment data reveals a stable relationship between Mylan Institutional and Mylan Laboratories Limited, as evidenced by the consistent volume of imports over the analyzed period. However, this dependency also presents potential risks, such as supply chain disruptions due to geopolitical events, regulatory changes, or operational challenges faced by the supplier. To mitigate these risks, Mylan Institutional may consider diversifying its supplier base and establishing contingency plans to ensure a continuous and reliable supply of pharmaceutical products.

2Supply Chain Resilience

Mylan Institutional's supply chain resilience is influenced by its sourcing strategy, which is heavily concentrated on a single supplier, Mylan Laboratories Limited. This concentration can pose challenges in maintaining a consistent supply of pharmaceutical products, especially in the face of potential disruptions such as natural disasters, political instability, or regulatory changes affecting the supplier's operations.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, approval, and marketing of pharmaceutical products. The FDA enforces a comprehensive framework of regulations to ensure the safety, efficacy, and quality of drugs entering the U.S. market.

Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA), which provides the legal foundation for the FDA's regulatory activities. The Drug Approval Process, as outlined by the FDA, involves rigorous evaluation of clinical data, manufacturing practices, and labeling information to grant marketing authorization for pharmaceutical products. For Indian generics to enter the U.S. market, they must undergo this approval process, demonstrating bioequivalence to the reference listed drug and compliance with Good Manufacturing Practice (GMP) standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent, necessitating compliance with FDA regulations. Manufacturers and importers must obtain an FDA Establishment Identifier (FEI) number and register their facilities with the FDA. Additionally, imported pharmaceutical products must be accompanied by a valid New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) approval, depending on the product type.

Mylan Institutional, Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Mylan Institutional's product category focus on antibiotics, gastrointestinal treatments, and oncology therapies aligns with prevailing market demands and therapeutic needs. The substantial importation of vancomycin, a critical antibiotic, underscores the company's commitment to addressing the ongoing challenges posed by antibiotic-resistant infections. Similarly, the inclusion of famotidine and ampicillin reflects the company's strategy to provide essential medications for gastrointestinal disorders and bacterial infections, respectively.

The importation of gemcitabine, an oncology drug, indicates Mylan Institutional's recognition of the growing demand for cancer treatments and its role in supplying vital therapies to the U.S. market. This product mix demonstrates the company's responsiveness to evolving healthcare needs and its dedication to enhancing patient outcomes across multiple therapeutic areas.

2Sourcing Profile

Mylan Institutional's sourcing strategy is characterized by a focus on finished pharmaceutical formulations, particularly from Indian manufacturers

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Mylan Institutional, Inc

What products does Mylan Institutional, Inc import from India?

Mylan Institutional, Inc imports 8 pharmaceutical products across 4 categories. Top imports: Vancomycin ($5.3M), Famotidine ($2.6M), Ampicillin ($1.2M), Doxycycline ($900.0K), Gemcitabine ($550.0K).

Who supplies pharmaceuticals to Mylan Institutional, Inc from India?

Mylan Institutional, Inc sources from 3 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (89.6% of imports, $1.2M).

What is Mylan Institutional, Inc's total pharmaceutical import value?

Mylan Institutional, Inc's total pharmaceutical import value from India is $11.5M, based on 250 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mylan Institutional, Inc focus on?

Mylan Institutional, Inc imports across 4 categories. The largest: Antibiotics (67.5%), Gastrointestinal (22.5%), Oncology (6.5%).

Get Full Mylan Institutional, Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.